Oxbryta (Voxelotor)
- Medicine Name: Oxbryta
- Generic Name: Voxelotor
- Dosage Form & Strength: Tablets: 500 mg and Tablets: 300 mg for Oral Suspension
- Manufactured By: Global Blood Therapeutics, Inc.
Oxbryta is a hemoglobin S polymerization inhibitor used for the treatment of sickle cell disease in adults and pediatric patients aged 4 years and older.
Recommended Dosage: The recommended dosage of Oxbryta tablets for adults and pediatric patients aged 12 years and older is 1,500 mg orally once daily either with or without meals. Patients should swallow tablets whole. Do not crush, cut, or chew the tablets. In case a dose is missed, or not administered entirely, resume dosing the following day. This medicinal product may be given with or without hydroxyurea.
The recommended dosage for pediatric patients aged 4 years to less than 12 years (select tablets or tablets for oral suspension) is based on patient’s ability to swallow tablets and patient weight. Once daily dose for patients with body weight 40 kg or greater, 20 kg to less than 40 kg, and 10 kg to less than 20 kg is 1,500 mg, 900 mg and 600 mg respectively.
Patients should disperse the tablets for oral suspension promptly before administration in a cup and in room temperature clear liquid (such as drinking water or clear soda) prior to swallowing. Do not swallow whole, crush, cut, or chew the Oxbryta tablets for oral suspension.
- Severe hypersensitivity reactions after the use of Oxbryta have occurred. Clinical manifestations may include generalized rash, mild shortness of breath, urticaria, mild facial swelling, and eosinophilia. If these reactions occur, discontinue treatment and administer apt medical therapy. Do not reinitiate treatment in patients who experience these signs/symptoms with previous use.
- The oxbryta 500 mg administration may interfere with measurement of Hb subtypes (HbA, HbS, & HbF) by high-performance liquid chromatography (HPLC). In case precise quantitation of Hb species is needed, chromatography needs to be done or performed.
- Due to the potential for severe adverse reactions in the breastfed child, including changes in the hematopoietic system, patients should avoid breastfeeding during treatment with oxbryta 500 mg tablet, and for at least 14 days after the final dose.
- The safety and effectiveness of Voxelotor for SCD have been established in pediatric patients aged 4 years and older. The safety and efficacy of this medicine in pediatric patients with SCD aged below 4 years have not been established.
What documents are required to import OXBRYTA to India?
OXBRYTA (voxelotor) tablets can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients id proof (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is OXBRYTA available in India?
OXBRYTA (voxelotor tablets) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability of Oxbryta in India (Ahmedabad, Mumbai, Kolkata, Hyderabad, Chennai, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
OXBRYTA can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of OXBRYTA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for Oxbryta 500 mg tablets price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source the OXBRYTA (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Oxbryta®?
Voxelotor is Generic Name for the trade name drug Oxbryta®.
What is the Manufacturer Name of Oxbryta®?
Oxbryta® is manufactured by Global Blood Therapeutics, Inc.
Is Oxbryta® approved by the FDA?
Yes, Oxbryta® is approved by the FDA. Date of approval: November 25, 2019.
Is Oxbryta® approved in EU?
Oxbryta is the first medication approved in Europe that directly blocks sickle hemoglobin (HbS) polymerization, the molecular basis of sickling and destruction of RBCs in SCD.
What is the dosage and form of Oxbryta® supplied?
Oxbryta® is supplied as Tablets: 500 mg for oral administration and Tablets: 300 mg for oral suspension.
What should I avoid while on treatment with Oxbryta®?
Avoid St. John’s wort while on treatment with Oxbryta.
What are the most common side effects due to Oxbryta®?
Most common side effects due to Oxbryta® include: rash, headache, abdominal pain, diarrhea, nausea, and pyrexia.
Most common side effects reported in pediatric patients aged 4 to <12 years are rash, pyrexia, abdominal pain, vomiting, diarrhea, and headache.
How much does Oxbryta® cost in India?
The oxbryta cost in India is reasonable and can vary. In order to procure this sickle cell disease drug authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Oxbryta®?
Store the tablets of Oxbryta at temperature 20°C to 30°C (68°F to 86°F).
Is it safe to buy Oxbryta® online in India?
Yes, You can buy oxbryta online in India legitimately and safely from https://www.indianpharmanetwork.in/ if the medication has not been approved or is not available in your country.
What are the Highlights of prescribing information for Oxbryta®?
Click Here to download full oxbryta prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.